Literature DB >> 8509216

p53 mutations in sporadic adrenocortical tumors.

H Ohgaki1, P Kleihues, P U Heitz.   

Abstract

Non-familial human adrenocortical adenomas and carcinomas were screened for mutations in exons 5-8 of the p53 tumor suppressor gene by single-strand-conformation-polymorphism (SSCP) analysis, followed by direct sequencing of PCR-amplified DNA. Point mutations in codons 12, 13 and 61 in H-ras, K-ras and N-ras proto-oncogenes were similarly assessed by direct DNA sequencing. Three out of 15 primary adrenocortical carcinomas (20%) contained a mis-sense point mutation in the conserved regions (exons 5 and 8) of the p53 gene. Mutations were located in codon 157 (GTC-->TTC; Val-->Phe), codon 163 (TAC-->AAC; Tyr-->Asn), and codon 273 (CGT-->TGT; Arg-->Cys). The mutation in codon 157 was detected in the primary tumor as well as in brain and lymph-node metastases. Among 18 adrenocortical adenomas, there was only a single non-miscoding mutation in codon 295 (CCT-->CCC; Pro-->Pro). These data suggest that mutational inactivation of the p53 gene occurs in a minority (20%) of sporadic adrenocortical carcinomas and that these mutations constitute a late event in the multi-step process of malignant transformation. No ras mutations were detected in any of these tumors, suggesting that these genes are not involved in the development of tumors originating from the adrenal cortex.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8509216     DOI: 10.1002/ijc.2910540310

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.

Authors:  Derek P Simon; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2012-01-13       Impact factor: 4.102

2.  Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.

Authors:  Junna Ye; Yan Qi; Weiqing Wang; Fukang Sun; Qin Wei; Tingwei Su; Weiwei Zhou; Yiran Jiang; Wenqi Yuan; Jianfei Cai; Bin Cui; Guang Ning
Journal:  Endocrine       Date:  2012-02-04       Impact factor: 3.633

Review 3.  A diagnostic approach to adrenal cortical lesions.

Authors:  Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

4.  Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis.

Authors:  Alexia Belavgeni; Stefan R Bornstein; Anne von Mässenhausen; Wulf Tonnus; Julian Stumpf; Claudia Meyer; Evelyn Othmar; Markus Latk; Waldemar Kanczkowski; Matthias Kroiss; Constanze Hantel; Christian Hugo; Martin Fassnacht; Christian G Ziegler; Andrew V Schally; Nils P Krone; Andreas Linkermann
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-14       Impact factor: 11.205

5.  Fluorescence-based mutation detection. Single-strand conformation polymorphism analysis (F-SSCP).

Authors:  J S Ellison
Journal:  Mol Biotechnol       Date:  1996-02       Impact factor: 2.695

Review 6.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

Review 7.  Hypermutability in carcinogenesis.

Authors:  B S Strauss
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

Review 8.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

9.  p53 protein and its messenger ribonucleic acid in human adrenal tumors.

Authors:  V Adleff; K Rácz; M Tóth; I Varga; A Bezzegh; E Gláz
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

10.  Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues.

Authors:  G P Bernini; A Moretti; P Viacava; A G Bonadio; P Iacconi; P Miccoli; A Salvetti
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.